Advertisement

The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma

      KRAS mutant non-small cell lung cancers (NSCLCs) vary in clinical outcome depending on which specific KRAS mutation is present. Shorter progression free survival has been associated with KRAS variants G12C and G12V. Cell lines with these variants depend to a greater extent on the RAS/RAF/MEK/ERK signaling pathway and become more susceptible to MEK inhibition. Because different KRAS mutations may lead to altered drug sensitivity, we aimed to determine specific KRAS mutation status in a NSCLC patient cohort at our institution. A total of 502 NSCLC samples were screened for somatic mutations using the 50 gene AmpliSeq™ Cancer Hotspot Panel v2 (CHPv2). However only samples positive for variants in the KRAS gene were included in this study. Variants identified in the KRAS genes were curated using publicly available databases. The overall mutation rate in the KRAS gene was 32.7% (164/502). The most common KRAS mutations were G12C (41%), G12V (19%), and G12D (14%) along with less frequent variants. After re-mining our sequencing data, we found that more than a half of our KRAS mutant NSCLC patients could potentially benefit from the addition of a MEK inhibitor such as selumetinib to standard chemotherapeutic agents. Due to mutated KRAS, these patients will likely fail traditional anti-EGFR therapies but be eligible for newer combination therapies.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Cancer Genetics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Rovigatti U.
        Cancer modelling in the NGS era—Part I: emerging technology and initial modelling.
        Crit Rev Oncol Hematol. 2015; 96: 274-307
        • Tsongalis G.J.
        • Peterson J.D.
        • de Abreu F.B.
        • et al.
        Routine use of the Ion Torrent AmpliSeq Cancer Hotspot Panel for identification of clinically actionable somatic mutations.
        Clin Chem Lab Med. 2014; 52: 707-714
        • Chong C.R.
        • Janne P.A.
        The quest to overcome resistance to EGFR-targeted therapies in cancer.
        Nat Med. 2013; 19: 1389-1400
        • Shaw A.T.
        • Engelman J.A.
        ALK in lung cancer: past, present, and future.
        J Clin Oncol. 2013; 31: 1105-1111
        • Ahearn I.M.
        • Haigis K.
        • Bar-Sagi D.
        • et al.
        Regulating the regulator: post-translational modification of RAS.
        Nat Rev Mol Cell Biol. 2011; 13: 39-51
        • Whyte D.B.
        • Kirschmeier P.
        • Hockenberry T.N.
        • et al.
        K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors.
        J Biol Chem. 1997; 272: 14459-14464
        • Ihle N.T.
        • Byers L.A.
        • Kim E.S.
        • et al.
        Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.
        J Natl Cancer Inst. 2012; 104: 228-239
        • Riely G.J.
        • Johnson M.L.
        • Medina C.
        • et al.
        A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations.
        J Thorac Oncol. 2011; 6: 1435-1437
        • Janne P.A.
        • Shaw A.T.
        • Pereira J.R.
        • et al.
        Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.
        Lancet Oncol. 2013; 14: 38-47
        • Janne P.A.
        • Smith I.
        • McWalter G.
        • et al.
        Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer.
        Br J Cancer. 2015; 113: 199-203
        • Martin P.
        • Leighl N.B.
        • Tsao M.S.
        • et al.
        KRAS mutations as prognostic and predictive markers in non-small cell lung cancer.
        J Thorac Oncol. 2013; 8: 530-542
        • Mascaux C.
        • Iannino N.
        • Martin B.
        • et al.
        The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis.
        Br J Cancer. 2005; 92: 131-139
        • Forbes S.A.
        • Beare D.
        • Gunasekaran P.
        • et al.
        COSMIC: exploring the world's knowledge of somatic mutations in human cancer.
        Nucleic Acids Res. 2015; 43: D805-D811
        • Cserepes M.
        • Ostoros G.
        • Lohinai Z.
        • et al.
        Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy.
        Eur J Cancer. 2014; 50: 1819-1828
        • Kim E.S.
        • Herbst R.S.
        • Wistuba I.I.
        • et al.
        The BATTLE trial: personalizing therapy for lung cancer.
        Cancer Discov. 2011; 1: 44-53
        • Mellema W.W.
        • Masen-Poos L.
        • Smit E.F.
        • et al.
        Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer.
        Lung Cancer. 2015; 90: 249-254
        • Hames M.L.
        • Chen H.
        • Iams W.
        • et al.
        Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer.
        Lung Cancer. 2016; 92: 29-34
        • Garassino M.C.
        • Marabese M.
        • Rusconi P.
        • et al.
        Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer.
        Ann Oncol. 2011; 22: 235-237
        • De Roock W.
        • Jonker D.J.
        • Di Nicolantonio F.
        • et al.
        Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
        JAMA. 2010; 304: 1812-1820
        • Bando H.
        • Yoshino T.
        • Yuki S.
        • et al.
        Clinical outcome of Japanese metastatic colorectal cancer patients harbouring the KRAS p.G13D mutation treated with cetuximab + irinotecan.
        Jpn J Clin Oncol. 2012; 42: 1146-1151
        • Tejpar S.
        • Celik I.
        • Schlichting M.
        • et al.
        Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.
        J Clin Oncol. 2012; 30: 3570-3577
        • Caunt C.J.
        • Sale M.J.
        • Smith P.D.
        • et al.
        MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road.
        Nat Rev Cancer. 2015; 15: 577-592